logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO-SITC 2019—Nivolumab + HS-110 vaccine shows safety, preliminary efficacy in advanced NSCLC

Adding HS-110 to nivolumab may result in greater antitumor activity than nivolumab alone.